19 / 27
allied
academies
Page 56
June 06-07, 2019 | London, UK
2
nd
International Conference on
Tissue Science and Molecular Biology,
Stem Cells & Separation Techniques
Joint Event
Biomedical Research (An International Journal of Medical Sciences) | ISSN: 0976-1683 Volume 30
Prospecting, development, optimization and clinical trial of new heterologous
fibrin sealant derived from snake venom: From bench to the bedside
Rui Seabra Ferreira Jr
Universidade Estadual Paulista (UNESP), Brazil
T
o bridge the GAP between basic and applied sciences is
neededtopushforwarddiseaseresearchandtherapeutics.
What types of drug leads are truly “druggable”, sit in
“patented bioproducts space” and can be pushed towards
clinical trials? We present one successful translational case of
bioproduct from laboratory bench to the bedside. Although
animal toxins present excellent candidate molecules because
they have high specificity for a cellular receptor without side
effects, few drugs are approved for human use. Considering
that infectious diseases could be transmitted via human blood
a new heterologous fibrin sealant (HFS) is proposed, whose
components are a serine protease (a thrombin-like enzyme)
extracted from the venom of
Crotalus durissus terrificus
snakes and a fibrinogen-rich cryoprecipitate extracted from
the blood of
Bubalus bubalis
buffaloes. This new bioproduct
has been used as a coagulant, sealant, adhesive and recently
as a scaffold candidate to bone and cartilage repair using
mesenchymal stem cells. Thus, we show its pre-clinical
applications aiming at repairing nervous system traumas
and bone regeneration. Also, we have finished an innovative
safety trial phase I/II to treat chronic venous ulcers concluding
that the product is safe and clinically promising candidate for
this purpose due its preliminary effectiveness.
e
:
rui.seabra@unesp.brBiomed Res, Volume 30
ISSN: 0976-1683